- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
- Interventions
- Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,154
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Common Warts
- Interventions
- Nanopulse System
- Device
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Cervical Cancer, Genital Warts
- Interventions
- Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 9 Years to 18 Years · Female only
- Enrollment
- 331 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
- Interventions
- Durvalumab, Tremelimumab, Poly-ICLC
- Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more
- Conditions
- Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
- Interventions
- virtual bronchoscopy
- Device
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus
- Interventions
- ATA3219
- Drug
- Lead sponsor
- Atara Biotherapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Thousand Oaks, California
- Conditions
- Infections, Herpesviridae
- Interventions
- Valaciclovir, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 17
- States / cities
- Carmichael, California • Davis, California • Riverside, California + 13 more
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
- Interventions
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- Medicenna Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 7
- States / cities
- San Diego, California • San Francisco, California • Santa Monica, California + 4 more
- Conditions
- HIV Infections, HIV Seronegativity, Lipodystrophy
- Interventions
- Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 10
- States / cities
- Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
- Interventions
- Cancer Therapeutic Procedure, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Herpes Simplex, HIV Infections
- Interventions
- Vidarabine, Acyclovir, Foscarnet sodium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more
- Conditions
- Skin Diseases, Infectious
- Interventions
- Trimethoprim-sulfamethoxazole, Placebo group
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Onychomycosis
- Interventions
- AN2690
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Bryan, Texas
- Conditions
- Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
- Interventions
- N/A This is an observational study
- Other
- Lead sponsor
- OM1, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anogenital Herpes, COVID-19, Herpes Labialis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 120 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Wart, Common Wart, Verruca Vulgaris, Verruca Plantaris, Plantar Wart
- Interventions
- duct tape occlusion therapy
- Device
- Lead sponsor
- Minneapolis Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Herpes Simplex, HIV Infections
- Interventions
- Crofelemer, Acyclovir
- Drug
- Lead sponsor
- Shaman Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 23 more
- Conditions
- Herpes Simplex
- Interventions
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 505 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more
- Conditions
- Tinea Pedis
- Interventions
- Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
- Drug
- Lead sponsor
- Douglas Pharmaceuticals America Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Brandon, Florida • Tampa, Florida
- Conditions
- HIV Infections
- Interventions
- Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Longbeach, California + 25 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- adalimumab, Placebo
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Bakerfield, California • Los Angeles, California + 15 more
- Conditions
- Latent Tuberculosis Infection, Tuberculosis
- Interventions
- Not listed
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- Not listed
- Enrollment
- 21,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Richmond, California • Denver, Colorado + 7 more
- Conditions
- Tinea Pedis
- Interventions
- Naftifine hydrochloride 2%, Placebo, Naftin® 2% (Naftifine hydrochloride 2%)
- Drug
- Lead sponsor
- Genzum Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 693 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 12
- States / cities
- Brandon, Florida • Miami, Florida • Miramar, Florida + 6 more
- Conditions
- Encephalitis, Herpes Simplex, Keratitis, Mouth Disease, Skin Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland